Informations:
Erreur:
ID
39579
Description
Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed); ODM derived from: https://clinicaltrials.gov/show/NCT00725842
Lien
https://clinicaltrials.gov/show/NCT00725842
Mots-clés
Versions (1)
- 31/01/2020 31/01/2020 -
Détendeur de droits
See clinicaltrials.gov
Téléchargé le
31 janvier 2020
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Hepatitis C NCT00725842
Eligibility Hepatitis C NCT00725842
- StudyEvent: Eligibility
Similar models
Eligibility Hepatitis C NCT00725842
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Study Subject Participation Status Willing
Item
the patient must demonstrate his/her continued willingness to participate in the study.
boolean
C2348568 (UMLS CUI [1,1])
C0600109 (UMLS CUI [1,2])
C0600109 (UMLS CUI [1,2])
Age
Item
the patient must be at least 18 years of age, of either gender.
boolean
C0001779 (UMLS CUI [1])
Chronic Hepatitis C Genotype Any | peginterferon alfa-2b
Item
patients with chronic hepatitis c (any genotype) who received peg-ifn alfa-2b +
boolean
C0524910 (UMLS CUI [1,1])
C1148363 (UMLS CUI [1,2])
C1552551 (UMLS CUI [1,3])
C0796545 (UMLS CUI [2])
C1148363 (UMLS CUI [1,2])
C1552551 (UMLS CUI [1,3])
C0796545 (UMLS CUI [2])
Ribavirin | Primary treatment Hepatitis C
Item
ribavirin as first treatment for hepatitis c.
boolean
C0035525 (UMLS CUI [1])
C1708063 (UMLS CUI [2,1])
C0019196 (UMLS CUI [2,2])
C1708063 (UMLS CUI [2,1])
C0019196 (UMLS CUI [2,2])
Hepatitis C RNA negative Assay
Item
negative hcv-rna at the end of treatment (24 or 48 weeks according to the product labeling as appropriate), measured by the assay used at each institution. only institutions using an assay with a limit of detection of 50 iu/ml or less will be eligible.
boolean
C0855841 (UMLS CUI [1,1])
C1510438 (UMLS CUI [1,2])
C1510438 (UMLS CUI [1,2])
Treatment completed | Peginterferon alfa-2b Plus Ribavirin
Item
patients who completed treatment with peginterferon alfa-2b plus ribavirin more than 4 weeks before study entry.
boolean
C0580352 (UMLS CUI [1])
C0796545 (UMLS CUI [2,1])
C0332287 (UMLS CUI [2,2])
C0035525 (UMLS CUI [2,3])
C0796545 (UMLS CUI [2,1])
C0332287 (UMLS CUI [2,2])
C0035525 (UMLS CUI [2,3])
Hepatitis C RNA positive | Treatment completed
Item
patients with positive hcv-rna at the end of treatment (24 or 48 weeks according to the product labeling as appropriate).
boolean
C0855842 (UMLS CUI [1])
C0580352 (UMLS CUI [2])
C0580352 (UMLS CUI [2])
Treatment Time period Inadequate
Item
patients treated for a period shorter than the enrollment period.
boolean
C0087111 (UMLS CUI [1,1])
C1948053 (UMLS CUI [1,2])
C0205412 (UMLS CUI [1,3])
C1948053 (UMLS CUI [1,2])
C0205412 (UMLS CUI [1,3])
Human immunodeficiency virus (HIV) coinfection
Item
patients co-infected with human immunodeficiency virus (hiv).
boolean
C4062778 (UMLS CUI [1])
HBV coinfection
Item
patients co-infected with hepatitis b virus (hbv).
boolean
C2242656 (UMLS CUI [1])
Contraceptive methods Inappropriate | Status post Treatment
Item
patients who do not use appropriate effective method of birth control after the end of treatment (according to legal recommendations).
boolean
C0700589 (UMLS CUI [1,1])
C1548788 (UMLS CUI [1,2])
C0231290 (UMLS CUI [2,1])
C0087111 (UMLS CUI [2,2])
C1548788 (UMLS CUI [1,2])
C0231290 (UMLS CUI [2,1])
C0087111 (UMLS CUI [2,2])